Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05241028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Name: Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer — clinical trial record (NCT05241028)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorHebei Medical University Fourth Hospital

Started2022-05-01

View on ClinicalTrials.gov ↗

Amendment history

2023-10-06

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2022-02→confirmed 2022-05-01

Study sitesdetails revised at 1 of 1 site

2022-02-06

Original filing

Hebei Medical University Fourth Hospital

53 trials monitored

See 1 trial at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion. Enrolled patients will take Ensatinib for 3 years or until recurrence of the disease or intolerable toxicity, following complete tumour resection with or without adjuvant standard chemotherapy.

Trial Details

NCT Number	NCT05241028
Lead Sponsor	Hebei Medical University Fourth Hospital
Conditions	Non-small Cell Lung Cancer
Enrollment	80 participants
Start Date	2022-05-01
Primary Completion	2027-02 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2023-10-10